Agilent Technologies (NYSE:A) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Agilent Technologies (NYSE:A) posted its quarterly earnings results on Wednesday. The medical research company reported $1.49 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.09, FiscalAI reports. The company had revenue of $1.84 billion during the quarter, compared to the consensus estimate of $1.80 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%. Agilent Technologies updated its FY 2026 guidance to 6.000-6.100 EPS and its Q3 2026 guidance to 1.480-1.500 EPS.

Agilent Technologies Trading Up 0.6%

Shares of A stock traded up $0.74 during trading hours on Wednesday, reaching $115.82. The company’s stock had a trading volume of 2,899,904 shares, compared to its average volume of 2,183,498. The stock has a market capitalization of $32.73 billion, a P/E ratio of 25.57, a P/E/G ratio of 2.42 and a beta of 1.22. Agilent Technologies has a one year low of $108.35 and a one year high of $160.27. The firm’s fifty day simple moving average is $114.91 and its 200 day simple moving average is $129.01. The company has a current ratio of 2.07, a quick ratio of 1.59 and a debt-to-equity ratio of 0.44.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Tuesday, June 30th will be given a $0.255 dividend. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, June 30th. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.52%.

Institutional Investors Weigh In On Agilent Technologies

Hedge funds have recently made changes to their positions in the company. State of Wyoming bought a new stake in shares of Agilent Technologies during the second quarter valued at approximately $35,000. Transamerica Financial Advisors LLC boosted its position in shares of Agilent Technologies by 180.8% during the fourth quarter. Transamerica Financial Advisors LLC now owns 337 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 217 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Agilent Technologies during the third quarter valued at approximately $49,000. DV Equities LLC bought a new stake in shares of Agilent Technologies during the fourth quarter valued at approximately $54,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Agilent Technologies during the fourth quarter valued at approximately $58,000. 87.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on A shares. Robert W. Baird raised their target price on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wall Street Zen cut Agilent Technologies from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen decreased their price objective on Agilent Technologies from $170.00 to $157.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Wells Fargo & Company decreased their price objective on Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating on the stock in a report on Thursday, February 26th. Finally, UBS Group reduced their price target on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $162.40.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent raised its FY 2026 outlook, guiding for EPS of $6.00-$6.10 and revenue of $7.4 billion-$7.5 billion, both in line to slightly above Wall Street expectations. The company also guided Q3 EPS to $1.48-$1.50 on revenue of $1.8 billion-$1.9 billion, signaling stable demand and execution.
• Positive Sentiment: Royal Bank of Canada initiated/started coverage with an Outperform rating and a $153 price target, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Robert W. Baird also raised its price target to $156 and reiterated an Outperform rating, reinforcing analyst confidence ahead of the next earnings cycle. Benzinga
• Neutral Sentiment: Recent product and conference announcements, including new GC systems, a MAM solution for biopharma quality control, and cancer research showcases, highlight ongoing innovation but are less likely to move the stock immediately.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.